 Braxia Scientific Corp, a medical research company with clinics providing novel psychedelic treatments for depression, revealed that it has hit a milestone by running the first Health Canada-approved multiple-dose psilocybin clinical trial which started with the first patients dosed in November this year. The trial, sponsored by the Brain and Cognition Discovery Foundation, is being conducted at the Canadian Rapid Treatment Center of Excellence CRTCE, which is a wholly-owned subsidiary of Braxia. 